Hormonal
Gradual, individualized dose escalation of GLP-1 receptor agonists is the primary clinical strategy to mitigate gastrointestinal side effects (nausea, vomiting, constipation) and improve treatment persistence in obesity management.
When starting a GLP-1 injection for weight loss, do not rush to the full dose. Start at the lowest possible dose and wait until you feel completely comfortable before asking your doctor to increase it. Eat smaller, low-fat meals and stay hydrated. If you feel nauseous, pause the increase; this is normal and usually goes away.
Gradual dose escalation is recommended in the prescribing information for most GLP-1RAs and may help reduce GI side effects [1,13], and should therefore be standard practice.
Why this rating
Based on expert consensus and clinical guidelines rather than a single high-quality RCT specifically testing titration schedules against fixed dosing for tolerability.
Source
Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice
Sean Wharton et al. · Postgraduate Medicine · 2021
DOI 10.1080/00325481.2021.2002616
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →